We performed double immunostaining of ISG15 and CD163 in the cohort of NPC biopsy samples for analyzing the correlation between numbers of ISG15+ TAM and NPC patients’ prognosis. This evidence concerns the gene CD163 and nasopharyngeal carcinoma.